QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=4FD711A71D7C22919E2D55A0F42BB902;jsessionid=318464DC06246D1973A91591DA97A77C;jsessionid=FC6833A2DD37404231EAFB7F4CCD604B;jsessionid=A61FD878190615547E89C92EC9B59416;jsessionid=BD791235BD3D4E3F6D7C8EE7E3752409;jsessionid=CA0374C21B6130FD96DAE45A0D1F3F1B;jsessionid=4749CAF235F3A6DA3E105D04C40848A9 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=C1188DFB6C25D0C9A6AAC30CD302840A;jsessionid=4FD711A71D7C22919E2D55A0F42BB902;jsessionid=318464DC06246D1973A91591DA97A77C;jsessionid=FC6833A2DD37404231EAFB7F4CCD604B;jsessionid=A61FD878190615547E89C92EC9B59416;jsessionid=BD791235BD3D4E3F6D7C8EE7E3752409;jsessionid=CA0374C21B6130FD96DAE45A0D1F3F1B;jsessionid=4749CAF235F3A6DA3E105D04C40848A9